To date, the controversial results on the predictive value of PD-L1 expression in NSCLC and response to PD-1/PD-L1 inhibitors do not allow for any conclusive consideration regarding the static assessment of PD-L1 as a biomarker8. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.